Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: OPTISON

« Back to Dashboard
Optison is a drug marketed by Ge Healthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has thirty-nine patent family members in twenty-seven countries.

The generic ingredient in OPTISON is albumin human. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

Summary for Tradename: OPTISON

Suppliers / Packagers: see list1

Pharmacology for Tradename: OPTISON

Clinical Trials for: OPTISON

CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children
Status: Active, not recruiting Condition: Vesico-Ureteral Reflux

A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
Status: Completed Condition: Echocardiography

Regadenoson Real Time Perfusion Imaging Trial-Optison
Status: Recruiting Condition: Coronary Artery Disease; Myocardial Perfusion Abnormalities

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors
Status: Completed Condition: Abdominal Neoplasms; Pelvic Neoplasms

Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
Status: Terminated Condition: Carotid Artery Disease

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).
Status: Completed Condition: Pulmonary Hypertension

The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals
Status: Recruiting Condition: Hypertension, Pulmonary

Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage
Status: Not yet recruiting Condition: Atrial Fibrillation

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients
Status: Recruiting Condition: Breast Cancer

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Status: Recruiting Condition: Renal Cell Carcinoma

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYes6,723,303<disabled>Y <disabled>
Ge Healthcare
albumin human
INJECTABLE;INJECTION020899-001Dec 31, 1997RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: OPTISON

Country Document Number Publication Date
Hong Kong1012564Dec 29, 2000
JapanH07501319Feb 09, 1995
Canada2273140May 20, 2003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn